

18th Annual Indy Hematology Review™



Organized by:

Indy Hematology Education, Inc.

Achieving tomorrow's outcomes through education today.™

Presented by:



**Community
Health Network**

in collaboration with

**MD Anderson
Cancer Network®**

A program of MD Anderson Cancer Center

2021 PROGRAM

Saturday, August 21, 2021
Westin Indianapolis | Indianapolis, Indiana



For more information on VENCLEXTA,
visit VENCLEXTAHCP.COM

abbvie

Genentech
A Member of the Roche Group

Distributed and marketed by AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064
Marketed by Genentech USA, Inc., 1 DNA Way, South San Francisco, CA 94080-4990
©2019 AbbVie Inc. and Genentech USA, Inc.



US-VNCCIL-190129/June 2019 Printed in USA

18TH ANNUAL INDY HEMATOLOGY REVIEW

TABLE OF CONTENTS

Letter from the Chairman.....	4
Sponsors and Supporters	7
Hematology Symposium Agenda.....	14
Nursing Symposium Agenda.....	15
General Information	13
Continuing Education Information.....	16
Faculty Biographies.....	18
T. Howard Lee Keynote	24
Meet our “NAME” Sponsor.....	27
Exhibitor Listing.....	28
Indy Hematology Education, Inc.....	29

Complimentary WIFI Log-in information:

Network: Indy Hematology Review

Password: Hematology21

*Disclosure information, biographies, and slides
(where authorized by the presenter) will be available
at www.indyhematologyreview.com*

The Pandemic: A DRIVE with Inclusion and Diversity

The pandemic of 2021 will forever be remembered for the changes it has wrought upon ours and the lives of the patients we care for. The Coronavirus (SARS COVID-19), a respiratory born illness with over two million deaths globally, may have as it's most lasting impact however, the illumination of preexisting fractures and fissures in our society. And in so doing, has exposed the lack of diversity that has plagued our clinical trials. Current clinical research trials, frequently do not enroll minorities of color, including African-Americans, Native-Americans, and Hispanic-Americans. Therefore, in evaluating ongoing clinical research, and emerging data in hematologic malignancies and non-malignant conditions, it is clear that we as providers have failed to ensure that data generated for efficacy and of adverse reactions are applicable to certain populations that we treat, even in diseases that disproportionately affect minorities. For example, Multiple myeloma occurs in 20% of African-Americans yet current major studies have less than 5% enrollment of African-American, African or black participants. Another glaring example is evaluation of the safety of agents for cardiovascular risks, hypertension, and diabetes, disorders that disproportionally affect persons of color who frequently are not included in these studies. The net effect of these examples are a mistrust of the "medical establishment", therefore, when a lifesaving vaccine is developed, but it is viewed with suspicion and, rejected or not embraced by persons of color who certainly have been significantly affected by the virus; we all wonder: WHY?

A DRIVE TO ACTION

We must like "onward soldiers marching out to war and victory" begin a 5-Step D.R.I.V.E. action plan to ensure HealthCare Justice by 2030 with clinical trial equity and diversity and inclusion being reached.

D.R.I.V.E.

D: All clinical trials must include a Diversity Officer who is tasked just like a DSMB in safety to ensure a diversity plan is established, maintained, and

modified during the course of each study to meet its accrual goals of inclusion and diversity.

R: Create a Ranking System for measuring the relative diversity of enrolled subjects in a clinical trial that are published with each trial.

I: Create an Individual/Personal diversity plan to ensure your minority patients are enrolled or participating in clinical research.

V: Verify and ensure that podium presentations at major conferences are preferentially given to clinical trials meeting diversity goals.

E: Encourage, train, and recruit minority investigators to participate in all clinical trials.

Finally, as we gather today for another successful Indy Hematology Review, we must evaluate the data presented critically and apply our knowledge equitably, in keeping with our slogan "Achieving Tomorrow's Outcomes Through Education Today".

Thank you to all attendees, sponsors, supporters, volunteers, meeting staff, and the unpaid Board of Directors of our non-profit Indy Hematology Education, Incorporated, and to Community Health Network, our named sponsor, for their tireless efforts and dedication to ensuring a successful meeting. I look forward to seeing all of you again on March 26, 2022, at our 19th Indy Hematology review here at the Westin Hotel.

Finally, please show your support for research diversity and inclusion in blood cancers and blood diseases at #DRIVE WITH IHE for diversity and inclusion in clinical research

Ruemu Ejedafeta Birhiray, M.D.





SECOND OPINIONS AVAILABLE WITH OUR MULTIDISCIPLINARY CANCER EXPERTS

Our highly specialized cancer physicians at Franciscan Health Cancer Center treat complex cancers and evaluate newly diagnosed cancer patients at our Second Opinion Clinic.

Let our team of experts develop a personalized cancer treatment plan for your patients, giving them access to clinical trials and innovative cancer therapies.

**SPEAK WITH OUR SECOND
OPINION NURSE NAVIGATOR**

(317) 528-1420



Franciscan HEALTH
CANCER CENTER

SPONSORS AND SUPPORTERS

We appreciate and sincerely thank those who support this Symposium for they are important to our success and continued ability to invite globally recognized faculty to present the most current information available. Spend time with them during the breaks and the other non-CME events.



Achieving tomorrow's outcomes through education today.™

Name Sponsor



Community

Health Network

in collaboration with

**MDAnderson
Cancer Network®**

A program of MD Anderson Cancer Center

Platinum Level

abbvie

janssen **Oncology**
PHARMACEUTICAL COMPANIES OF **Johnson & Johnson**

Gold Level

AstraZeneca



morphosys

Silver Level

BeiGene

SANOFI **GENZYME**

Bronze Level

ALEXION®

AstraZeneca



Karyopharm®
Therapeutics



SPONSORS AND SUPPORTERS (CONTINUED)

Product Theater Supporters



An AbbVie Company



Physicians Lounge



Nurse Scholarships

Indiana Community Cancer Care Foundation, Inc.

Sponsor



*Super Supporters – We appreciate
the generous marketing support these
companies have offered*

Adaptive Biotechnologies
American Oncology Network
Bristol Myers Squibb
Community Health Network
Indiana Oncology Society

Jazz Pharmaceuticals
Kite Pharma
Rigel Pharmaceuticals
Seagen
Tempus

*The 2021 Indy Hematology Review is supported by
educational grants from:*

AstraZeneca | Bristol Myers Squibb
Lilly USA LLC | Novartis

*A special thanks to An Evening
with The Experts Sponsors*





venetoclax tablets 10mg, 50mg, 100mg

For more information on VENCLEXTA,
visit VENCLEXTAHCP.COM

abbvie

Genentech
A Member of the Roche Group

Distributed and marketed by Abbvie Inc., 1 North Waukegan Road, North Chicago, IL 60064
Marketed by Genentech USA, Inc., 1 DNA Way, South San Francisco, CA 94080-4990
©2019 Abbvie Inc. and Genentech USA, Inc.



venetoclax tablets 10mg, 50mg, 100mg

US-VNCLL-190129/June 2019 Printed in USA

LEARN MORE ABOUT A SUBCUTANEOUS TREATMENT OPTION

 **DARZALEX Faspro™**
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

Learn more at darzalexhcp.com/faspro.

© Janssen Biotech, Inc. 2020
12/20 cp-160390v2

INDIANA ONCOLOGY SOCIETY

*PROVIDING A VOICE FOR INDIANA'S MULTIDISCIPLINARY CANCER
CARE TEAMS AND THE PATIENTS THEY SERVE SINCE 2009*

Serving a diverse community of cancer care professionals from across Indiana, IOS delivers educational programs, networking opportunities, and robust advocacy support to help practices stay ahead of the shifting healthcare landscape and respond to the challenges of delivering quality cancer care.

Visit IOS-INDIANA.COM to explore our state-specific resources, live educational programs, and membership benefits.



IOS-INDIANA.COM

[@OSSatACCC](https://twitter.com/OSSatACCC)



“AON helps us take care of our business so **we can focus on our patients.**”

Ruemu E. Birhiray, MD

Hematology Oncology of Indiana,
an AON partner

Delivering better care **together.**

Meet the American Oncology Network, the fastest growing network of community oncology practices delivering local access to exceptional cancer care. With an expanding network of partner practices across 17 states, we provide the comprehensive support, ancillary services and proven practice management expertise to enable physicians to focus on what matters most – providing the highest quality care and outcomes for their patients.

Visit **AONcology.com** for more information on career opportunities and joining the network.



Physician Led. Practice Proven.®

Arizona | Arkansas | Georgia | Idaho | Indiana | Iowa | Kentucky
Louisiana | Maryland | Michigan | Missouri | Nevada | North Carolina
Ohio | South Carolina | Virginia | Washington


CALQUENCE[®]
(acalabrutinib) 100 mg capsules

CALQUENCE

CONFIDENCE

Explore the latest data from key
CALQUENCE clinical trials



Explore more at calquencehcp.com

CALQUENCE is a registered trademark of the AstraZeneca group of companies.
©2021 AstraZeneca. All rights reserved. US-54389 6/21

AstraZeneca 

 **VENCLEXTA**[®]
venetoclax tablets 10mg, 50mg, 100mg

For more information on VENCLEXTA,
visit VENCLEXTAHCP.COM

abbvie

Genentech
A Member of the Roche Group

Distributed and marketed by AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064
Marketed by Genentech USA, Inc., 1 DNA Way, South San Francisco, CA 94080-4990
©2019 AbbVie Inc. and Genentech USA, Inc.

 **VENCLEXTA**[®]
venetoclax tablets 10mg, 50mg, 100mg

US-VNCCLL190129/June 2019 Printed in USA

GENERAL INFORMATION



This activity is brought to you by
Indy Hematology Education, Inc.

Achieving tomorrow's outcomes through education today.™

Registration Desk Hours:

7:00 a.m. – 2:30 p.m.

*The Registration Desk is located on
the 2nd Floor in the Grand Ballroom
Foyer.*

Exhibit Display Hours:

7:00 a.m. – 4:45 p.m.

*Displays are located next door to
the Symposium Room in Grand
Ballroom 1-3.*

Attendee Engagement Activity

While you are in the Exhibit area, take the Bingo card you were given at registration and find the exhibitors who match the moves you need to make to win the Bingo (down, across, diagonal) and have exhibitor stamp the box with exhibitor's name on it. Drop your completed Bingo card by the Registration Desk. Be present at 4:40pm to win prizes (iPad, Gift Cards and more).

Complimentary WIFI Log-in information:

Network: Indy Hematology Review

Password: Hematology21

Presentation Website:

www.indyhematologyreview.com

Photography

Photos of attendees will be taken throughout the Symposium. These photos are for Indy Hematology Review and Indy Hematology Education, Inc. use only and may appear on the IHR website, in promotional brochures, or other future promotional material. By virtue of your attendance, you agree to usage of your photograph in such media, unless we are notified in writing along with a clear photo of yourself.

Safety Precautions

By attending the Indy Hematology Review you voluntarily assume all risks related to your health and well-being. Currently (as of July 27, 2021) there is no mask mandate, but you are encouraged to wear one and practice healthy habits.

3 ways to contact Indy Hematology Review:

email: Indyhr@conventionmanagers.com

or visit: www.indyhematologyreview.com

or call: 317-841-7171 for assistance.

Friday, August 20, 2021

6:00 p.m.

Dinner Product Theaters
Capitol 1, 3 & Cabinet (1st Floor)

Symposium Agenda, Saturday, August 21, 2021

All sessions are in Grand Ballroom 4 – 5 (2nd Floor), unless otherwise noted.

7:00 a.m. – 2:30 p.m.

Registration | Grand Ballroom Foyer

7:00 a.m. – 4:45 p.m.

Exhibit displays | Grand Ballroom 1-3

7:30 a.m. – 8:15 a.m.

Breakfast Product Theaters | Capitol Ballroom 1 & 3,
Council (1st Floor) and House (2nd Floor)

8:30 a.m.

*State of the Art: 2021 Emerging Therapies in Hematologic
Malignancies* | Ruemu E. Birhiray, MD

8:55 a.m.

Multiple Myeloma: The Cure Around the Corner | Kenneth
Anderson, MD

9:25 a.m.

Waldenström's Macroglobulinemia: Targeting for the BIG Kill |
Steven Treon, MD, MA, PhD, FACP, FRCP

9:55 a.m.

*Chronic Myeloid Leukemia: Therapy Updated and Modified
for 2021* | Richard Larson, MD

10:25 a.m.

Visit Exhibitors for a chance to win prizes, enjoy
refreshments in the Physicians Lounge | Q & A |
Grand Ballroom 1-3

10:45 a.m.

*Indolent and Mantle Cell Lymphoma: Updating the Toolbox,
Including and Beyond Anti-CD20 Antibodies* | Sonali Smith,
MD, FASCO

11:15 a.m.

Aggressive B and T Cell Lymphomas: Emerging Therapies |
John Leonard, MD

11:45 a.m.

*Acute Lymphoblastic Leukemia: Biologic and Targeted
Therapy* | Hagop Kantarjian, MD

12:15 p.m.

Benign Hematology: Clotting, Bleeding and More | Craig
Kessler, MD

12:45 p.m.

Visit Exhibitors for a chance to win prizes | Q & A | Grand
Ballroom 1-3

1:00 p.m. – 1:45 p.m.

Luncheon Product Theaters | Capitol Ballroom 1 & 3
& Council (1st Floor) & House (2nd Floor)

2:00 p.m.

T. HOWARD LEE KEYNOTE LECTURE*State of the Art: Current and Emerging Treatment of
Hodgkin's Lymphoma* | Ranjana Advani, MD

2:45 p.m.

Challenging Cases Presentation | Michael Wiemann, MD, FACP

3:10 p.m.

*Chronic Lymphocytic Leukemia: Curability and Duration of
Therapy* | Steven Coutre, MD

3:40 p.m.

*Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
in 2021: The Cheson Approach* | Bruce Cheson, MD, FACP,
FAAAS, FASCO

4:10 p.m.

*Myeloproliferative Neoplasms: Risk Stratification and
Therapy; A 2021 Global Perceptive* | Ruben Mesa, MD,
FACP

4:40p.m.

Visit Exhibitors for a chance to win prizes, enjoy
refreshments in the Physicians Lounge | Q & A | Prize
Drawing | Grand Ballroom 1-3

4:50 p.m.

*Mastocytosis and Eosinophilia: The Vexing Disorders of the
Blood* | Ayalew Tefferi, MD

SYMPOSIUM AGENDA

5:20 p.m.	<i>Acute Myeloid Leukemia: Finally, A Trip Beyond 7+3</i> Harry Erba, MD, PhD
5:50 p.m.	<i>Myelodysplastic Syndrome: Emerging and Targeted Therapies</i> Richard Stone, MD
6:20 p.m.	<i>Hematopoietic Stem Cell Transplantation: Updating the Old Closet</i> Rear Admiral Richard Childs, MD
6:50 p.m.	Q & A
7:00 p.m.	Wrap Up Symposium
7:05 p.m.	Hematologic Malignancies Town Hall Reception Grand Ballroom Foyer
7:05 p.m. - 8:35 p.m.	<i>Hematologic Malignancies Town Hall</i> Grand Ballroom 4-5 Ruemu E. Birhiray, MD Moderator Steven Coutre, MD CLL/Chronic Leukemia Morie Gertz, MD, MACP Myeloma/Amyloidosis/Plasma Cell Disorders Jessica Altman, MD Acute Leukemia Jennifer Woyach, MD CLL Charles Schiffer, MD Acute and Chronic Leukemia Bruce Cheson, MD, FACP, FAAAS, FASCO Lymphoma and CLL

NURSING & ALLIED PROVIDERS SYMPOSIUM AGENDA

All sessions are scheduled in Capitol Ballroom 2 (1st Floor), unless otherwise noted.

Moderators: Donna M. Birhiray, OTR, MBA and Thalia Hammond

8:30 a.m.	<i>State of the Art: 2021 Emerging Therapies in Hematologic Malignancies</i> Ruemu E. Birhiray, MD Grand Ballroom 4 - 5
9:00 a.m.	<i>Management of Long-Term Survivors of Hematologic Malignancies</i> Kristi Orbaugh, RN, MSN RNP, AOCN
9:30 a.m.	<i>Benign Hematology and Coagulopathy</i> Craig Kessler, MD
10:00 a.m.	Visit Exhibitors for a chance to win prizes, enjoy refreshments in the Physicians Lounge Q & A Grand Ballroom 1-3
10:10 a.m.	<i>Aggressive Lymphomas</i> John Leonard, MD
10:40 a.m.	<i>Chronic Lymphocytic Leukemia</i> Steven Coutre, MD
11:10 a.m.	Visit Exhibitors for a chance to win prizes, enjoy refreshments in the Physicians Lounge Q & A Grand Ballroom 1-3
11:20 a.m.	<i>Myeloproliferative Neoplasms</i> Ruben Mesa, MD, FACP
11:45 a.m.	<i>Indolent Lymphomas and Hodgkin's Lymphoma</i> Sonali Smith, MD, FASCO
12:10 p.m.	<i>Recognizing Toxicities of Oral Oncolytics in the Management of Hematologic Malignancies</i> David Reeves, PharmD, BCOP
12:35 p.m.	<i>Multiple Myeloma and Waldenström's</i> Morie Gertz, MD, MACP
12:55 p.m.	Visit Exhibitors for a chance to win prizes Q & A Grand Ballroom 1-3
1:00 p.m. – 1:45 p.m.	Luncheon Product Theaters Capitol Ballroom 1 & 3 & Council (1 st Floor) & House (2 nd Floor)
2:00 p.m.	Join Main Program for Keynote Lecture and the Sessions that follow Grand Ballroom 4 - 5

CONTINUING EDUCATION INFORMATION

The 2021 Indy Hematology Review is supported by educational grants from:

**AstraZeneca | Bristol Myers Squibb
Lilly USA LLC | Novartis**

Evaluations will be open until September 17th and must be completed to receive CE credits

PHYSICIANS



To receive CE, you must attend the entire Symposium from 8:30 am – 6:50 pm. Successful completion of this CME activity requires participants to complete a post-Evaluation.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program for the conference and 1.50 points for the Town Hall. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

LEARNING OBJECTIVES (ACCME, ANCC, ACPE)

1. Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promyelocytic, and Myeloproliferative neoplasms.
2. Evaluate molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström's Macroglobulinemia to assist in disease recognition.
3. Discuss the advancement of immune check point inhibitors within hematologic malignancies and updated treatment paradigms presented at the American Society of Hematology meeting, December 2020.
4. Recommend new regimens for Hematopoietic Stem Cell transplantation and identification of transplant candidates.
5. Review the advancement in hematology research and treatment of diseases of coagulopathy, compliment and cytopenia.
6. Review current and emerging treatment regimens in lymphomas.
7. Review and update advances in the treatment of disorders of compliment and aplastic anemia.
8. Present challenging clinical cases and discuss management strategies of hematologic malignancies and disorders with the application of current and emerging medical literature.

CME ACCREDITATION STATEMENT

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Indy Hematology Education, Inc. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION STATEMENT

Purdue University College of Pharmacy designates this live activity for a maximum of 8.75 AMA PRA Category 1 Credit(s)[™]. Symposium – 8:30 am - 6:50 pm. Purdue University College of Pharmacy designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)[™] (Town Hall Interactive Meeting - 7 - 8:30 pm). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE STATEMENT

All faculty, staff, and reviewers involved in the planning, review, or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff, and reviewers of Indy Hematology Education, Inc. and Purdue University College of Pharmacy have no relationships to disclose.

NOTE: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.

NURSES

To receive CE, you must attend the entire Symposium from 8:30 am – 6:50 pm. Successful completion of this CME activity requires participants to complete a post-Evaluation.

NCPD Accreditation Statement

Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Successful completion of this nursing continuing professional development activity will be awarded 8.5 contact hours (Symposium: 8:30 am - 6:50 pm). This program is approved for 1.50 contact hours (Town Hall Interactive Meeting: 7 - 8:30 pm).

PHARMACISTS



To receive CE, you must attend the entire Symposium from 8:30 am – 6:50 pm. Successful completion of this CME activity requires participants to complete a post-Evaluation.

CPE ACCREDITATION STATEMENT

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution.

Symposium: 8:30 am - 6:50 pm.

Universal Activity Number (UAN): 0018-9999-21-012-L01-P
This program is approved for 8.5 contact hours (0.85 CEU's).

Town Hall Interactive Meeting: 7 - 8:30 pm.

Universal Activity Number (UAN): 0018-9999-21-013-L01-P
This program is approved for 1.5 contact hours (0.15 CEU's).

For a complete bio on any of our distinguished faculty visit our website
www.indyhematologyreview.com/faculty-speakers/

Ruemu E. Birhiray, MD

Partner, Hematology Oncology of Indiana, a Division of American Oncology Network and President, Indy Hematology Education Inc. Clinical Professor, Marian University College of Osteopathic Medicine (Indianapolis, IN)

Dr. Birhiray is an attending physician in medical oncology, hematology, and hematopoietic stem cell transplantation at Hematology-Oncology of Indiana, and at St. Vincent Hospital in Indianapolis, IN. After completing his internal medicine residency at Columbus Hospital in Chicago where he also served as Chief Medical Resident in 1994, he was a postgraduate fellow in bone marrow transplant at Johns Hopkins University in Baltimore and in medical oncology at the National Cancer Institute, National Institutes of Health in Bethesda, Maryland.

Michael Wiemann, MD, FACP

Vice President, Indy Hematology Education, Inc., President of Providence Hospital, Executive Vice President West Region, St. John Providence Health System (Warren, MI)

Dr. Wiemann is the President of the Ascension Medical Group, Michigan, and Clinical Professor of Medicine at Michigan State University College of Human Medicine. Dr. Wiemann is a medical oncologist and Co-Founder of the Indy Hematology Review. While in Indianapolis, he held several leadership positions at St. Vincent Hospital and Health Center, including Medical Director of Oncology, Chief Medical Officer, and Interim President.

Jessica Altman, MD

Professor, Department of Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine (Chicago, IL)

Dr. Altman serves as Director of the Acute Leukemia Program at Robert H. Lurie Cancer Center of Northwestern University and Director of the Leukemia Program for Northwestern Medicine Developmental Therapeutics Institute and Chair, Robert H. Lurie Comprehensive Cancer Center Clinical Trial Audit Committee. She serves on the NMH Committee on Infection Control and NUCATS Internal Advisory Board.

Kenneth Anderson, MD

Kraft Family Professor of Medicine, Harvard Medical School, Program Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (Boston, MA)

Over the last four decades, he has developed laboratory and animal models of myeloma in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies. He has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies, which have markedly improved patient outcome.

Bruce Cheson, MD, FACP, FAAS, FASCO

Formerly Frank M. Ewing Foundation Chair in Hematology-Oncology, Professor of Medicine, Head of Hematology and Cellular Therapy, Director of Center for Lymphoid Malignancies, and Deputy Chief, Hematology-Oncology at Georgetown University Hospital, Lombardi Comprehensive Cancer Center (Washington, DC)

Dr. Cheson is Editor in Chief of Annals of Lymphoma, former Editor-in-Chief of Clinical Advances in Hematology and Clinical Lymphoma, Leukemia and Myeloma, and Associate Editor of the Journal of Clinical Oncology. He is currently Scientific Advisor to the Lymphoma Research Foundation and is on its Scientific Advisory Board. His interests focus on the development and evaluation of new therapeutic approaches for hematologic malignancies and measures of response.

Rear Admiral Richard Childs, MD

Clinical Director, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (Bethesda, MD)

Dr. Childs oversees the entire clinical research portfolio of the institute's intramural research divisions in cardiology, pulmonary medicine, hematology/oncology, and populations sciences. Dr. Childs research focuses on allogeneic stem cell transplantation and tumor immunology to treat aplastic anemia, hematological malignancies, and solid tumors.

Steven Coutré, MD

Professor of Medicine in the Division of Hematology at the Stanford University School of Medicine in Stanford, USA (Palo Alto, CA)

Steven Coutré is a member of the American Society of Hematology, American Society of Clinical Oncology, the National Cancer Institute Leukemia Steering Committee, and serves as Vice Chair of the Leukemia Committee of the Southwest Oncology Group. Professor Coutré's research interests focus on translational clinical research for hematologic malignancies, particularly CLL.

2021 FACULTY

Harry Erba, MD, PhD

Professor of Medicine, Division of Hematologic Malignancies and Cellular Therapy Director, Duke Leukemia Program, Chair, SWOG Leukemia Committee, Duke University (Durham, NC)

Dr. Erba graduated from Yale University with a Bachelor of Science degree in Biology. He earned his medical degree and Doctor of Philosophy degree in Biophysics from Stanford University School of Medicine in California. He completed his internship, residency and fellowship at Brigham and Women's Hospital. He has served as the Chair of the SWOG Leukemia Committee since 2012.

Morie Gertz, MD, MACP

Roland Seidler Jr. Professor, Art of Medicine, Chair Emeritus, Department of Internal Medicine, Mayo Clinic (Rochester, MN)

Dr. Gertz is a Master of the American College of Physicians. His undergraduate degree was awarded with highest distinction from Northwestern University graduating Phi Beta Kappa.

Hagop M. Kantarjian, MD

Professor and Chair, Department of Leukemia, Samsung Distinguished Leukemia Chair in Cancer Medicine the University of Texas, MD Anderson Cancer Center (Houston, TX)

Dr Kantarjian's research focuses on translational-clinical developmental therapeutics in leukemia. In the past 3 decades, he has made several contributions that improved patient prognosis and survival with chronic myeloid leukemia, in acute lymphocytic leukemia, the discovery of decitabine for the treatment of myelodysplastic syndrome, and of clofarabine for the treatment of leukemias, among others.

Craig Kessler, MD

Professor of Medicine and Pathology and attending physician in the Division of Hematology-Oncology at Georgetown University Medical Center (Washington, DC)

He also serves as the Director of the Division of Coagulation in the Department of Laboratory Medicine and is the Director of the Therapeutic and Cellular Apheresis Unit. With a distinguished career beginning in 1973, Dr. Kessler earned his medical degree from Tulane University School of Medicine in New Orleans, Louisiana. He remained in New Orleans to complete his medical internship and residency before moving to Baltimore, Maryland, in 1976 to assume a Fellowship in Special Hematology at Johns Hopkins Hospital.

Richard Larson, MD

Professor of Medicine in Hematology/Oncology, Director of Hematologic Malignancies Clinical Research Program, the University of Chicago Comprehensive Cancer Center (Chicago, IL)

Dr. Larson is Professor of Medicine in the Section of Hematology/Oncology and Director of the Hematologic Malignancies Clinical Research Program at the University of Chicago. He received his medical degree from the Stanford University School of Medicine in 1977, and completed his postdoctoral training in Internal Medicine, Hematology, and Medical Oncology at the University of Chicago. Since 1983 he's been a faculty member in the Section of Hematology/Oncology and the Comprehensive Cancer Center, University of Chicago.

John Leonard, MD

John P. Leonard, MD, is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and Senior Associate Dean for Innovation and Initiatives at Weill Cornell Medicine (New York, NY)

Dr. Leonard is Executive Vice Chairman of the Weill Department of Medicine at Weill Cornell Medicine and New York-Presbyterian Hospital, where he also serves as Attending Physician. Dr. Leonard's primary research interest is in the development of novel therapeutic strategies for the treatment of lymphoma and related hematologic malignancies, and he has lectured at major international meetings on these topics.

Ruben Mesa, MD, FACP

Executive Director of the Mays Cancer Center, at UT Health San Antonio MD Anderson Cancer Center (San Antonio, TX)

Having joined UT Health in 2017, Dr. Mesa began as Director of the cancer center. After earning degrees in nuclear engineering and physiology, with minors in radiation biophysics and bioengineering, from the University of Illinois at Urbana-Champaign, Dr. Mesa received his medical degree from the Mayo Graduate School at the Mayo Clinic College of Medicine in Rochester, Minnesota.

Kristi Orbaugh, RN, MSN RNP, AOCN

Adult Nurse Practitioner, Community Hospital Oncology Physicians (Indianapolis, IN)

Kristi Orbaugh MSN, RNP, AOCN has spent her entire career in the oncology field. She received her undergraduate degree from Purdue University and her master's degree from Indiana University Purdue University of Indianapolis. She works at Community Hospital Cancer Center North which is an affiliate of MD Anderson as a nurse practitioner. She has published several oncology related articles.

David Reeves, PharmD, BCOP

Associate Professor of Pharmacy Practice, College of Pharmacy and Health Sciences, Butler University, Clinical Pharmacy Specialist in Hematology/Oncology, Franciscan Physician Network Oncology/Hematology Specialist (Indianapolis, IN)

David is an associate professor of pharmacy practice for the College of Pharmacy and Health Sciences at Butler University and clinical pharmacy specialist in hematology/oncology at Franciscan Physician Network Oncology/Hematology Specialists in Indianapolis, IN.

Charles Schiffer, MD

Emeritus Professor of Oncology and previously the Joseph Dresner Chair for Hematologic Malignancies and Director of the Leukemia/Lymphoma Multidisciplinary Program at Wayne State University School of Medicine and the Karmanos Cancer Institute (Detroit, MI)

Dr. Schiffer has authored and co-authored more than 350 articles and 80 book chapters on topics concerning the treatment of leukemia in adults, platelet transfusion, and granulocyte transfusion therapy, among others.

Sonali Smith, MD, FASCO

Elwood V. Jensen Professor of Medicine, Interim Section Chief of Hematology/Oncology, and Director of the Lymphoma Program at the University of Chicago's Department of Medicine (Chicago, IL)

Dr. Smith is a clinical investigator in lymphoma and a clinical expert in mature lymphoid malignancies including Hodgkin and non-Hodgkin lymphomas. As faculty member at the University of Chicago since 2001, she has written or co-written dozens of clinical trials, and has participated in many more with key input in the clinical design, determination of endpoints, and analysis. She is particularly interested in targeted agents and pathway inhibitors.

Richard Stone, MD

Chief of Staff and Director of Translational Research, Adult Leukemia Program, Professor of Medicine, Harvard Medical School Dana-Farber Cancer Institute (Boston, MA)

Richard Stone, MD, is the Chief of Staff at Dana-Farber Cancer Institute (DFCI). He is also Director of Translational Research for the Leukemia Division of Medical Oncology at DFCI, and Professor of Medicine at Harvard Medical School. He is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies including acute leukemia, myeloproliferative disorders, and myelodysplastic syndrome.

Ayalew Tefferi, MD

Barbara Woodward Lips II Professor of Medicine at the Mayo Clinic (Rochester, MN)

Dr. Tefferi's research interest is primarily focused on myeloid neoplasms including acute myeloid leukemia and chronic myeloid neoplasms. His web of science core collection publications, as of 6/3/2021, number over 1500 with an H-index of 120. He has participated in hundreds of invited lectureships including service as core faculty for GW, MDACC and Harvard annual board review courses.

Steven Treon, MD, MA, PhD, FACP, FRCP

Professor of Medicine, Harvard Medical School, Senior Attending Physician for Medical Oncology at DFCI and Brigham & Women's Hospital, Director of the Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute and Chair of the WM Clinical Trials Group (Boston, MA)

Using whole-genome sequencing, Dr. Treon's laboratory first identified highly recurring activating mutations in MYD88 and CXCR4 in WM patients and was the first to report that Bruton's tyrosine kinase (BTK) was a downstream target of the MYD88 L265 mutation, resulting in a study leading to the first-ever approval of a drug (ibrutinib) for WM. His current focus is in developing novel agents directed at mutated MYD88 and CXCR4 signaling.

Jennifer Woyach, MD

Professor in the division of Hematology, the Section Chair of Chronic Lymphocytic Leukemia (CLL), and a Physician Scientist focused on translational research in CLL at the Ohio State University (Columbus, OH)

Her laboratory interests include experimental therapeutics in CLL with a focus on signaling pathways and kinase inhibition. She has extensive experience studying BTK inhibitors, resistance mechanisms associated with irreversible BTK inhibitors, and strategies to overcome resistance.





Ranjana Advani, MD

Saul A. Rosenberg Professor of Lymphoma at Stanford University School of Medicine and Physician Leader of the Lymphoma Clinical Care Program (Stanford, CA)

Dr Advani specializes in research and treatment of Hodgkin and non-Hodgkin lymphomas and has developed a broad collaborative investigative program, encompassing clinical trials and translational correlates.

She is the Principal Investigator on numerous clinical trials. She currently serves on the National Comprehensive Cancer Network (NCCN) non-Hodgkin and Hodgkin Lymphoma (vice chair) guidelines panel, Lymphoma Core Committee of the Eastern Cooperative Oncology Group (ECOG) and the National Cancer Institute Lymphoma Steering Committee.

Dr Advani's fellowship was at Stanford University Hematology and Oncology in 1996. She completed her residency at Stanford University Internal Medicine Residency in 1990, Internship, Santa Clara Valley Medical Center Internal Medicine, residency in 1987, Board Certification by the American Board of Internal Medicine, Medical Oncology in 1995 and it all began with her medical education at Bombay University, India in 1982.



T. Howard Lee, MD

*Founder and President Emeritus,
Hematology Oncology of Indiana,
PC (Indianapolis, IN)*



The following individuals have been presenters and award recipients at the annual T. Howard Lee Keynote Lecture:

2003: Professor Bertrand Coiffier, MD

Bertrand Coiffier is Professor of Hematology at the Department of Hematology, Hospices Civils de Lyon and the University Claude Bernard, Lyon, France, Chairman, GELA

2004: Kanti Rai, MD

Past President of American Society of Hematology, ASH, Chief, Division of Hematology/Oncology, Long Island Jewish Medical Center, Professor of Medicine, Albert Einstein College of Medicine

2005: Claire Dearden, MBBS

Dr Claire Dearden is Consultant Hematologist and Head of the Chronic Lymphocytic Leukemia (CLL) Unit at The Royal Marsden and The Institute of Cancer Research, and Medical Director of the South West London Cancer Network.

2006: Sandra Horning, MD

Professor of Oncology, Sanford University, Past President of The American Society of Oncology, ASCO

2007: Lewis R. Silverman, MD

Director, Myelodysplastic Syndrome and Myeloproliferative Disease Program, Mount Sinai School of Medicine, New York, NY

2008: Neal Young, MD

Chief of the Hematology Branch of the National Heart, Lung and Blood Institute, National Institute of Health, Bethesda, MD

2009: Professor Michael Pfreundschuh, MD

Professor and Director of Medical Oncology, Department of Internal Medicine, Saarland University, and Chairman, German Lymphoma Group

2010: James Armitage, MD

Past President of ASCO, Joe Shapiro Professor of Medicine, and Past Dean, University of Nebraska Medical School, Omaha, NE

2011: Michael Keating, MBBS

Professor of Medicine and Internist, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

2012: Kenneth Anderson, MD

Kraft Family Professor of Medicine, Department of Medicine, Harvard Medical School, Medical Director, Kraft Family Blood Center, Dana-Farber Cancer Institute, Boston, MA

Continues on next page

Continued from previous page

2013: Susan O'Brien, MD

Ashbel Smith Professor and Chief of the Section of Acute Lymphocytic Leukemia, Department of Leukemia at the University of Texas MD Anderson Cancer Center

2014: Ross Levine, MD

Associate Attending Physician at Memorial Sloan-Kettering Cancer Center, Associate Professor of Medicine at Weill Cornell Medical College, New York, NY

2015: Stephen Ansell, MD, PhD

Professor of Medicine, Mayo Clinic Department of Hematology at the Mayo Clinic, MN

2016: David Porter, MD

Abramson Cancer Center, University of Pennsylvania Health System, Jodi Fisher Horowitz Professor of Leukemia Care Excellence
Director, Blood and Marrow Transplantation, Philadelphia, PA

2017: Bruce Cheson, MD

Deputy Chief, Division of Hematology/Oncology in the Department of Medicine, Head of Hematology and Professor of Medicine, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC

2018: Thomas Kipps, MD, PhD

Deputy Director of Research, Moores UCSD Cancer Center; Professor of Medicine UC San Diego, School of Medicine, San Diego, CA

2019: Pier Luigi Zinzani, MD, PhD

Professor of Hematology, Head of Lymphoma Group, Institute of Hematology, "L. e A. Seràgnoli", University of Bologna, Bologna, Italy

2020 Edward Stadtmauer, MD

Professor of Medicine and Section Chief of the Hematologic Malignancies in the Division of Hematology-Oncology at the Hospital of the University of Pennsylvania, Philadelphia, PA

2021: Ranjana Advani, MD

Saul A. Rosenberg Professor of Lymphoma at Stanford University School of Medicine and Physician Leader of the Lymphoma Clinical Care Program, Stanford, CA

Plan to attend the 19th Annual Indy Hematology Review
Saturday, March 26, 2022
The Westin Indianapolis

MEET OUR "NAME" SPONSOR



Community

Health Network

in collaboration with

**MD Anderson
Cancer Network®**

A program of MD Anderson Cancer Center

Since 2012, Community Health Network has been affiliated with MD Anderson Cancer Network®, a quality program of MD Anderson Cancer Center. All five Community hospital locations providing qualified cancer service, as well as our highly qualified physicians, have met the rigorous standards to treat cancer patients with MD Anderson evidence-based guidelines and best practices. These are disease-specific guidelines for cancer treatment, cancer prevention, early detection, and follow-up care, incorporating latest technologies, targeted therapies, immunotherapy, precision, and genetic treatments.

SAVE THE DATE!

2022 Indy Hematology Review

Saturday, March 26, 2022

3 ways to contact Indy Hematology Review:

email: Indyhr@conventionmanagers.com

or visit: www.indyhematologyreview.com

or call: 317-841-7171 for assistance.

EXHIBITOR LISTING

as of 7/27/2021

AbbVie Oncology	Janssen Pharmaceuticals
AbbVie	Jazz Pharmaceuticals
Acceleron	Kadmon
Adaptive BioTechnologies	Karyopharm Therapeutics
Alexion Pharmaceuticals	Kite Pharma
Alnylam Pharmaceuticals	Kyowa Kirin
Amgen	Mercy Health Physicians
Apellis Pharmaceuticals	MorphoSys
Astellas Pharma	Novartis
AstraZeneca	Novartis Pharmaceuticals
BeiGene Ltd	Novo Nordisk, Inc
Bristol Myers Squibb	Omeros Corporation
Coherus BioSciences	Oncopeptides
Community Health Network	Pharmacyclics LLC
Exact Sciences	PharmaEssentia USA
Exelixis	Rigel Pharmaceuticals
Foundation Medicine	Sanofi Genzyme
Genetech	Seagen
GlaxoSmithKline	Servier Pharmaceuticals
Guardant Health	Stemline Therapeutics
Incyte Corporation	Taiho Oncology, Inc.
Indiana Oncology Society	Takada Pharmaceuticals
Ipsen Biopharmaceuticals	Tempus
Janssen Oncology	

3 ways to contact Indy Hematology Review:

email: Indyhr@conventionmanagers.com
or visit: www.indyhematologyreview.com
or call: 317-841-7171 for assistance.

Indy Hematology Education, Inc.



Achieving tomorrow's outcomes through education today.™

Indy Hematology Education, Inc, is a 501(c), non-profit corporation, incorporated on February 15, 2010, in the State of Indiana, with the following purposes:

- (a) Raise awareness and provide education regarding hematology and oncology diseases and disorders
- (b) To encourage youth to pursue careers in hematology and oncology, and
- (c) To connect individuals suffering from or affected by hematology and oncology diseases and disorders to organizations, programs, and service providers.

BOARD OF DIRECTORS

Ruemu E. Birhiray, MD, President and CEO
Michael Wiemann, MD, FACP Vice-President
Donna M. Birhiray, OT, MBA, Treasurer and COO
Jennifer Terry, JD, Secretary
Thalia Hammond, Director of Conventions

INDY HEMATOLOGY REVIEW PLANNING COMMITTEE

Ruemu Birhiray, MD (Chair)
CEO, Indy Hematology Education Inc.
Partner and Vice President,
Hematology Oncology of Indiana, PC

Michael C. Wiemann, MD, FACP (Co-Chair)
VP, Indy Hematology Education Inc.
Providence Hospital/St. John Health Senior VP, CMO

Donna Birhiray, OTR, MBA
Indy Hematology Education Inc.
Treasurer and COO

Thalia Hammond
Indy Hematology Education Inc.
Director of Conventions

Jennifer Wheeler-Terry, JD
Indiana Legal Services, Secretary

Debbie Locklear
Meeting Services Unlimited Inc.
President

Tina Machina, CMP
Meeting Services Unlimited Inc.
Director of Conventions



SAVE THE DATE!

2022 Indy Hematology Review
Saturday, March 26, 2022





WE TRAIN YOUR CELLS TO FIGHT CANCER

the future of cancer treatment is here

We are a leader in cellular therapy, providing first-in-the-world, innovative approaches, such as CAR T-Cell immunotherapy to treat cancer. This is a new FDA approved individualized immunotherapy for use in patients with relapsed diffuse large B-cell lymphomas, follicular lymphoma, mantle cell lymphoma and lymphoblastic leukemia.



Franciscan HEALTH
CANCER CENTER

(317) 528-5500 • FranciscanHealth.org



Exclusive. Certified. Close to home.

That's what Community Health Network brings to patients facing cancer in Central Indiana.

Thanks to our affiliation with MD Anderson Cancer Network®—a program of MD Anderson Cancer Center — Community has access to more research and clinical trials than any other provider in the state. Groundbreaking therapies, best practices and the latest technology are in the hands of more than 40 certified physicians in your community, so world-renowned care is never far from home.

[*eCommunity.com/cancer*](http://eCommunity.com/cancer)



Community
Health Network

MD Anderson
~~Cancer~~ Network®
Certified Member